Retatrutide 10 mg by Hilma Biocare is a next-generation, triple-hormone receptor agonist designed for advanced metabolic and endocrine research. Often referred to as a "Triple-G" compound, Retatrutide simultaneously targets three distinct metabolic pathways: GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and Glucagon receptors. This synergistic mechanism makes it one of the most powerful and heavily researched peptides for energy expenditure, glycemic control, and metabolic regulation.

• Active Substance: Retatrutide 10 mg / vial

• Manufacturer: Hilma Biocare

• Form: Lyophilized Research Peptide Vial

• Quality Standard: HPLC Tested / Pharmaceutical Grade

Key Benefits:

• Triple Action Mechanism: Simultaneously stimulates GLP-1, GIP, and Glucagon receptors for comprehensive metabolic modulation.

• Enhanced Energy Expenditure: Glucagon receptor agonism supports increased lipid oxidation and thermogenic activity.

• Advanced Research Profile: Manufactured to stringent pharmaceutical standards with verified HPLC purity for precise laboratory studies.

Frequently Asked Questions (FAQ)

• Q: How is Retatrutide typically reconstituted and stored?

  A: It is reconstituted using a precise quantity of bacteriostatic water and must be stored in standard refrigeration (2–8°C) before and after mixing.

• Q: What makes Retatrutide different from standard GLP-1 agonists like Tirzepatide or Semaglutide?

  A: While Semaglutide targets GLP-1 and Tirzepatide targets GLP-1 and GIP, Retatrutide adds a third pathway (Glucagon receptor agonism), significantly boosting metabolic rate and fat oxidation.

• Q: What scientific areas focus on Retatrutide research?

  A: Researchers study its effects on metabolic syndrome, insulin sensitivity, body weight regulation, and lipid metabolism.